Motavizumab
From Wikipedia, the free encyclopedia
Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009[update], it is undergoing Phase II and III clinical trials.[1]
In December 2010, AstraZeneca in a stock market statement stated that it would be writing down $445m (£286m) after discontinuing a key development programme for Motavizumab. The company stated that it would no longer develop Motavizumab for the prevention of respiratory syncytial virus (RSV), and as a result was withdrawing its licence application to the US Food and Drug Administration. It added that it would continue to develop Motavizumab for other treatments of RSV.[2]
[edit] References
[edit] External links
|
|
|
| Fungal ("-fung-") |
|
|
| Viral ("-vi(r)-") |
|
|
| Bacterial ("-ba(c)-") |
|
Human ("-bacu-")
|
|
|
|
Mouse ("-baco-")
|
|
|
|
|
|
|
|
Humanized ("-bazu-")
|
|
|
|
| Toxin ("-tox(a)-") |
|
|
|
|
|
|
|
|
| Products |
|
|
Predecessors and
acquired companies |
|
|
| People |
|
|
|
|
|
(what is this?) (verify)
